腺苷脱氨酶-2诱导的人视网膜血管内皮细胞高通透性可被微小RNA-146b-3p抑制
本研究探讨腺苷脱氨酶-2(ADA2)在糖尿病视网膜炎症及内皮屏障功能障碍中的作用,以及微小RNA(miR)-146b-3p的治疗潜力。结果显示糖尿病玻璃体中ADA2活性显著升高,Amadori糖化白蛋白处理的巨噬细胞条件培养基可增加人视网膜内皮细胞通透性、破坏ZO-1并上调ICAM-1,而miR-146b-3p可逆转上述改变。作者认为抑制ADA2可能是保护血视网膜屏障功能的工具。
要点
- 糖尿病玻璃体中腺苷脱氨酶-2(ADA2)活性显著升高。
- Amadori糖化白蛋白处理的巨噬细胞条件培养基增加人视网膜内皮细胞(hRECs)通透性并破坏ZO-1。
- miR-146b-3p可逆转ADA2及巨噬细胞条件培养基诱导的hRECs通透性增加、ZO-1破坏和白细胞黏附。
核心结论
- 腺苷脱氨酶-2(ADA2)通过巨噬细胞来源的细胞因子参与糖尿病视网膜病变中血视网膜屏障(BRB)的破坏。
- 作者认为,用miR-146b-3p抑制ADA2可能是保护糖尿病视网膜病变中BRB功能的有用工具。
研究设计与样本
- 本研究为实验室研究,检测糖尿病者人玻璃体中ADA2活性,使用人单核细胞系U937分化为巨噬细胞并用Amadori糖化白蛋白(AGA)处理,以条件培养基处理人视网膜内皮细胞(hRECs)。
- 研究评估了ADA2活性、TNF-α和IL-6水平、hRECs通透性、ZO-1免疫荧光及白细胞黏附(MPO活性和ICAM-1表达)。
主要发现
- 糖尿病者人玻璃体中ADA2活性显著升高。
- AGA处理使人巨噬细胞中ADA2活性及TNF-α、IL-6水平显著升高。
- AGA处理的巨噬细胞条件培养基显著增加hRECs通透性、破坏ZO-1形态,并通过上调ICAM-1增加白细胞对hRECs的黏附。
- 上述改变均被miR-146b-3p逆转。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We recently demonstrated that adenosine deaminase-2 (ADA2) contributes to diabetic retinopathy (DR) via up-regulating the production of inflammatory cytokines in macrophages. Also, microRNA (miR)-146b-3p has the ability to inhibit ADA2. The goal of this study was to investigate the potential role of ADA2 and therapeutic benefit of miR-146b-3p in retinal inflammation and endothelial barrier dysfunction during diabetes. METHODS: Adenosine deaminase-2 activity was determined by colorimetric method in diabetic human vitreous. Human monocyte cell line U937 was differentiated into macrophages and then treated with amadori glycated albumin (AGA), and conditioned medium (CM) was used to assess the changes in ADA2 activity and TNF-α and IL-6 levels by ELISA. Also, macrophages were transfected with miR-146b-3p before treatment with AGA. Permeability of human retinal endothelial cells (hRECs) was assessed by electric cell-substrate impedance sensing (ECIS) after treatment with macrophage CM. Zonula occludens (ZO)-1 was examined by immuno-fluorescence in hRECs. Leukocyte adhesion was assessed in hRECs by measuring myeloperoxidase (MPO) activity and intercellular adhesion molecule-1 (ICAM-1) expression. RESULTS: Adenosine deaminase-2 activity was significantly increased in diabetic human vitreous. ADA2 activity and TNF-α and IL-6 levels were significantly increased in human macrophages by AGA treatment. Amadori glycated albumin-treated macrophage CM significantly increased hREC permeability, disrupted ZO-1 pattern, and increased leukocyte adhesion to hRECs through up-regulating ICAM-1. All these changes were reversed by miR-146b-3p. CONCLUSIONS: Adenosine deaminase-2 is implicated in breakdown of the blood-retinal barrier (BRB) in DR through macrophages-derived cytokines. Therefore, inhibition of ADA2 by miR-146b-3p might be a useful tool to preserve BRB function in DR.
引用
- Samra YA, Saleh HM, Hussein KA, et al. Adenosine Deaminase-2-Induced Hyperpermeability in Human Retinal Vascular Endothelial Cells Is Suppressed by MicroRNA-146b-3p. Invest Ophthalmol Vis Sci. 2017. PMID: 28170537. doi:10.1167/iovs.16-19782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。